Paper Details

  1. Home
  2. Paper Details

How I treat refractory and relapsed acute myeloid leukemia.

Author: DöhnerHartmut, GanserArnold, TholFelicitas R

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Acute myeloid leukemia (AML) is a type of blood cancer that is often difficult to treat. Most patients with AML develop refractory/relapsed disease, meaning that the cancer comes back even after treatment. While there are some targeted therapies available for specific subgroups of R/R AML, the best option for many patients is allogeneic hematopoietic cell transplantation (HCT). This procedure replaces the patient’s bone marrow with healthy bone marrow from a donor, and it is the only potentially curative strategy for R/R AML. New therapies are being developed, but it is important for patients to enroll in clinical trials to access these treatments.
Paper Details　
Original Abstract of the Article :
The majority of patients with acute myeloid leukemia (AML) develops refractory/relapsed (R/R) disease even in the presence of novel and targeted therapies. Given the biological complexity of the disease and differences in front-line treatments, there are only approved therapies for subgroups of R/R ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1182/blood.2023022481

データ提供：米国国立医学図書館（NLM）

Refractory and Relapsed Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a type of cancer that affects the bone marrow. This research paper explores the treatment of refractory/relapsed (R/R) AML, a condition where AML returns after treatment or does not respond to initial treatment. The authors discuss the challenges of treating R/R AML and review current and emerging therapies. They emphasize the importance of allogeneic hematopoietic cell transplantation (HCT) as a potentially curative option for many patients. The paper also highlights the importance of managing measurable residual disease (MRD) to prevent relapse. This research provides a comprehensive overview of the current landscape of R/R AML treatment and identifies promising areas for future research.

The Fight Against Relapsed AML: A Complex Challenge

Treating R/R AML is a complex challenge, but this research highlights the importance of personalized therapy and the ongoing development of new treatment strategies. The authors discuss the importance of HCT, MRD monitoring, and the use of targeted therapies to improve treatment outcomes. This research provides valuable insights for clinicians and researchers working to improve the lives of patients with R/R AML.

Navigating the Desert of Relapsed Leukemia

Relapsing leukemia is a challenging diagnosis, but this research provides hope for the future. By understanding the complex mechanisms of R/R AML and developing new treatment strategies, we can provide better care for patients and improve their chances of survival.

Dr. Camel's Conclusion

This research is like a wise camel, navigating the vast and unforgiving desert of relapsed AML, seeking new paths to healing and survival. The authors provide a comprehensive overview of the current treatment landscape and highlight the need for ongoing research and innovation. Their findings are a reminder that even in the face of complex medical challenges, we can find new ways to provide hope and relief to patients battling cancer.

Date :
  1. Date Completed n.d.
  2. Date Revised 2023-11-09
Further Info :

Pubmed ID

37944143

DOI: Digital Object Identifier

10.1182/blood.2023022481

Related Literature

Article Analysis
・Effects of gilteritinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.